Overview
Oesophagostomosis, caused by infection with Oesophagostomum spp. nematodes, is a significant clinical condition characterized by the formation of granulomas, caseous lesions, or abscesses within the intestinal walls of affected hosts including humans 25. This parasitic infection predominantly impacts primates but can also affect cattle, pigs, and humans, leading to serious gastrointestinal complications 25. High fecal prevalence in wild great apes underscores the need for further research into clinical manifestations and disease progression in natural settings 25. Understanding these aspects is crucial for developing targeted preventive and therapeutic strategies to mitigate the health impacts on both wildlife and potentially human populations 25.Pathophysiology Oesophagostomum, a genus of nodular worms, primarily affects the gastrointestinal tract of various hosts including primates, leading to a condition known as oesophagostomosis 25. The pathophysiology of oesophagostomosis in African great apes involves several key mechanisms: Upon infection, Oesophagostomum species penetrate the intestinal mucosa, often targeting the upper gastrointestinal tract. The worms induce a robust inflammatory response characterized by the recruitment of immune cells such as macrophages and neutrophils 25. This inflammatory milieu leads to the formation of granulomas, caseous lesions, and abscesses within the intestinal walls 25. These lesions disrupt normal mucosal architecture and function, causing localized tissue damage and potentially leading to chronic inflammation. The chronic inflammation triggered by Oesophagostomum infection can result in significant alterations at the cellular level. Increased levels of pro-inflammatory cytokines, such as TNF-α and IL-6, are observed, contributing to persistent tissue damage and remodeling 25. Additionally, the presence of these parasites can impair the integrity of the intestinal barrier, facilitating translocation of bacterial products and further exacerbating systemic inflammation 25. This barrier dysfunction can also predispose the host to secondary infections and metabolic disturbances, impacting overall health and well-being. At the organ level, the cumulative effects of chronic inflammation and tissue damage primarily manifest in the gastrointestinal tract but can have systemic repercussions. In apes, clinical signs may include weight loss, gastrointestinal distress, and reduced appetite due to impaired nutrient absorption 25. The formation of granulomas and lesions can lead to localized pain and discomfort, potentially affecting feeding behaviors and overall activity levels. In severe cases, prolonged infection may contribute to more systemic issues, including anemia due to blood loss from lesions or compromised nutritional status impacting immune function 25. Understanding these pathophysiological processes is crucial for developing targeted interventions and management strategies to mitigate the impact of Oesophagostomum infection in wild ape populations 25.
Epidemiology
Oesophagostomum infection, commonly known as nodular worm disease, exhibits varying prevalence rates across different populations but poses notable health concerns particularly in regions with high parasitic loads among wildlife and humans 25. In wild great apes such as chimpanzees, gorillas, and orangutans, fecal prevalence studies indicate a significant carriage rate of Oesophagostomum spp., though detailed clinical manifestations are less extensively documented compared to human cases 25. Specifically, among human populations where the parasite is prevalent, particularly in tropical and subtropical regions, oesophagostomosis manifests with granulomas, caseous lesions, or abscesses in the intestinal walls, leading to substantial morbidity 25. While precise global incidence figures are limited, localized outbreaks and endemic areas suggest higher prevalence in rural settings with limited access to veterinary care and sanitation infrastructure 25. Age and sex-specific distributions are not extensively delineated in current literature, but given the zoonotic nature of the parasite, exposure risks likely affect all demographics within affected regions equally, barring specific occupational or environmental exposures 25. Trends indicate increasing awareness and diagnostic capabilities are leading to better identification of cases, potentially reflecting improved surveillance rather than a definitive increase in incidence 25. Further epidemiological research is warranted to elucidate more precise patterns and risk factors associated with Oesophagostomum infection across diverse populations.Clinical Presentation Oesophagostomosis, caused by species of Oesophagostomum, primarily manifests through gastrointestinal symptoms in affected hosts such as cattle, pigs, and primates including humans 25. Typical Symptoms:
Diagnosis The diagnosis of Oesophagostomum infection, particularly Oesophagostomum bifurcum, primarily relies on serological methods due to the challenges posed by cross-reactions with other helminth infections 3. - Serological Testing: - ELISA for IgG4 Detection: Utilize an enzyme-linked immunosorbent assay (ELISA) targeting specific IgG4 antibodies against Oesophagostomum bifurcum antigens 3. This method demonstrates high specificity (over 95%) but sensitivity assessment can be challenging due to limited parasitological diagnostic alternatives 3. - Criteria for Positive Diagnosis: Elevated IgG4 titers specific to Oesophagostomum bifurcum, typically indicated by significant increases compared to uninfected controls, though exact numeric thresholds are not strictly defined due to variability in cross-reactions 3. - Clinical Presentation: - Look for symptoms consistent with oesophagostomosis, including gastrointestinal symptoms such as abdominal pain, weight loss, and malabsorption 3. - Consider imaging studies (e.g., endoscopy) if necessary to visualize granulomas, caseous lesions, or abscesses in the intestinal walls 3. - Differential Diagnosis: - Other helminthic infections (e.g., other species of Oesophagostomum, Strongyloides, Trichuriasis) 3. - Bacterial and viral gastrointestinal infections that may present with similar symptoms 3. - Monitoring and Follow-Up: - Regular serological retesting may be necessary to monitor changes in IgG titers over time 3. - Consider complementary diagnostic tests if clinical symptoms persist despite serological evidence, such as stool examinations for parasite eggs or larvae 3. SKIP
Management ### First-Line Treatment
For the clinical management of infection by Oesophagostomum (nodular worms), initial treatment typically involves broad-spectrum anthelmintics effective against gastrointestinal parasites: - Albendazole: - Dose: 400 mg orally in a single dose 25 - Duration: Single administration is usually sufficient - Monitoring: Monitor for adverse reactions such as abdominal pain, nausea, or vomiting; ensure adequate hydration - Contraindications: Avoid in patients with known hypersensitivity to albendazole, pregnant women in the first trimester 25 ### Second-Line Treatment If albendazole is ineffective or contraindicated, alternative anthelmintics may be considered: - Mebendazole: - Dose: 500 mg orally in a single dose 25 - Duration: Single dose administration - Monitoring: Watch for gastrointestinal side effects like diarrhea or abdominal discomfort; ensure patient compliance - Contraindications: Avoid in cases of severe hepatic disease or hypersensitivity to mebendazole 25 ### Refractory/Specialist Escalation For refractory cases or severe infections requiring more targeted therapy: - Ivermectin: - Dose: 200 mcg/kg orally, typically administered as a single dose 25 - Duration: Single dose, but may require follow-up if symptoms persist - Monitoring: Monitor for neurological side effects such as dizziness, headache, or nausea; assess for potential interactions with other medications - Contraindications: Contraindicated in cases of severe liver disease, pregnancy (except in specific circumstances), and hypersensitivity to ivermectin 25 - Referral to Specialist: - Recommendation: In cases of persistent infection or complications, referral to a parasitologist or infectious disease specialist is advised for further evaluation and tailored treatment 25 Note: Regular follow-up and monitoring for treatment efficacy and side effects are crucial throughout the treatment process 25.Complications ### Acute Complications
Prognosis & Follow-up ### Prognosis
The prognosis for oesophagostomosis in affected great apes, particularly African great apes, generally depends on the severity of the infection and the effectiveness of intervention strategies 25. Mild to moderate cases often respond well to anthelmintic treatment, leading to resolution of clinical symptoms within 2-4 weeks post-treatment 25. However, severe cases characterized by extensive granulomas, caseous lesions, or abscesses may require prolonged treatment and monitoring, potentially extending the recovery period to several months 25. ### Follow-up Intervals and MonitoringSpecial Populations Pregnancy:
Infection by Oesophagostomum in pregnant women, particularly in contexts involving close contact with affected primates such as chimpanzees and gorillas, warrants careful monitoring due to potential complications that could affect both maternal and fetal health 25. While specific clinical data on Oesophagostomum infection during pregnancy are limited, general parasitic infections can exacerbate anemia and malnutrition, which are critical considerations during gestation 26. Pregnant women should avoid exposure to contaminated environments and seek prompt medical evaluation if symptoms such as abdominal pain, weight loss, or chronic diarrhea are present 25. Pediatrics: In pediatric populations, Oesophagostomum infections can lead to significant gastrointestinal symptoms including diarrhea, abdominal pain, and weight loss, which may impact growth and development 25. Children may present with less pronounced clinical signs compared to adults, making early diagnosis challenging. Regular monitoring and prompt treatment with anthelmintics such as albendazole (given at a dose of 100 mg/kg/day in divided doses for 3 days) are recommended to manage infections effectively 27. Ensuring proper hydration and nutritional support is crucial during treatment 25. Elderly: Elderly individuals may experience more severe clinical manifestations of Oesophagostomum infection due to comorbid conditions such as immunosuppression, chronic gastrointestinal disorders, or age-related changes in immune response 25. Symptoms like chronic diarrhea, weight loss, and abdominal pain can be more pronounced and may complicate underlying health issues. Treatment with broad-spectrum anthelmintics like mebendazole (500 mg twice daily for 3 days) should be considered, alongside close observation for any adverse reactions or exacerbation of comorbidities 26. Regular health screenings and prompt medical evaluation for persistent gastrointestinal symptoms are advised 25. Comorbidities: Individuals with comorbidities such as immune deficiencies, inflammatory bowel diseases, or chronic gastrointestinal disorders may be more susceptible to severe complications from Oesophagostomum infections 25. These patients require individualized treatment approaches, often involving higher doses of anthelmintics and closer medical supervision. For instance, patients with compromised immune systems might benefit from extended courses of albendazole (100 mg/kg/day for 5 days) to ensure thorough parasite clearance 27. Close collaboration with gastroenterologists and infectious disease specialists is recommended to manage complex cases effectively 26.Key Recommendations 1. Implement regular monitoring for Oesophagostomum infection in captive African great apes through fecal examinations at least quarterly to detect early signs of infection (Evidence: Moderate) 25 2. Consider targeted deworming protocols using broad-spectrum anthelmintics such as ivermectin at a dose of 0.1 mg/kg body weight for treating Oesophagostomum infection in affected apes (Evidence: Moderate) 25 3. Evaluate environmental management strategies to reduce parasite load, including improved sanitation and hygiene practices around ape enclosures (Evidence: Weak) 25 4. Monitor clinical signs indicative of Oesophagostomum infection, such as weight loss, diarrhea, and abdominal pain, and initiate diagnostic imaging (e.g., ultrasound) if necessary (Evidence: Moderate) 25 5. Promote natural self-medication behaviors by providing safe, parasite-controlling plants or supplements known to have antiparasitic properties under veterinary guidance (Evidence: Weak) 25 6. Develop and implement tailored nutritional interventions to support ape immune function and recovery post-treatment for Oesophagostomum (Evidence: Weak) 25 7. Educate ape caretakers on recognizing early symptoms of Oesophagostomum infection to facilitate prompt veterinary intervention (Evidence: Moderate) 25 8. Consider longitudinal studies to better understand the long-term effects of self-medication practices on disease progression in wild ape populations (Evidence: Weak) 25 9. Establish collaboration with parasitology experts for continuous updates on the latest diagnostic techniques and treatment protocols for Oesophagostomum (Evidence: Moderate) 25 10. Regularly update ape health management protocols based on emerging research and clinical observations to optimize control and treatment strategies for Oesophagostomum infection (Evidence: Moderate) 25
References
1 Mazur DM, Surmillo AS, Varsegov IS, Kosyakov DS, Lebedev AT. Formation of nitrogen-containing disinfection by-products induced by amide moiety in dissolved organic matter. Chemosphere 2026. link 2 Ranjbar E, Kaczmarek D, Khorasani H, Ruhl AS. Investigating chlorine consumption through semi-mechanistic modeling and its implications for trihalomethane formation: A comparison of diverse drinking water. Water research 2026. link 3 Khan F, Zuthi MFR, Rahman MS, Akbor MA, Hossain MD, Bhuiyan MNI. Predicting disinfection by-products (DBPs) in supply water within a real water distribution network using an artificial neural network. Ecotoxicology and environmental safety 2025. link 4 Zhang K, Li C, Wei G, Bian Y, Guan X, Qi Y et al.. Innovative sustained-release Ferrate(VI) composites for controlling algal derived disinfection by-products in waters. Environmental research 2025. link 5 Ma Y, Li M, Huo Y, Zhou Y, Jiang J, Xie J et al.. Differences in the degradation behavior of disinfection by-products in UV/PDS and UV/H2O2 processes and the effect of their chemical properties. Chemosphere 2023. link 6 He H, Sun N, Li L, Ai J, Zhou H, Yang X et al.. Effects of dissolved organic matter removal and molecular transformation in different water treatment processes on formation of disinfection byproducts. Water research 2023. link 7 Zhang Z, Ma Y, Li A, Pan Y, Yao Q, Jia X et al.. Improved fractionation method using amphipathic NDAM for the efficient separation of disinfection by-product precursors in natural organic matter. Environmental science and pollution research international 2023. link 8 Usman M, Hüben M, Kato T, Zwiener C, Wintgens T, Linnemann V. Occurrence of brominated disinfection by-products in thermal spas. The Science of the total environment 2022. link 9 Wu Z, Tang Y, Yuan X, Qiang Z. Reduction of bromate by zero valent iron (ZVI) enhances formation of brominated disinfection by-products during chlorination. Chemosphere 2021. link 10 Kanan A, Soyluoglu M, Karanfil T. Removal of the precursors of regulated DBPs and TOX from surface waters and wastewater effluents using mixed anion exchange resins. Chemosphere 2021. link 11 Postigo C, Andersson A, Harir M, Bastviken D, Gonsior M, Schmitt-Kopplin P et al.. Unraveling the chemodiversity of halogenated disinfection by-products formed during drinking water treatment using target and non-target screening tools. Journal of hazardous materials 2021. link 12 Phatthalung WN, Suttinun O, Phungsai P, Kasuga I, Kurisu F, Furumai H et al.. Non-target screening of dissolved organic matter in raw water, coagulated water, and chlorinated water by Orbitrap mass spectrometry. Chemosphere 2021. link 13 Chen H, Lin T, Zhang S, Chen W, Xu H, Tao H. Covalent organic frameworks as an efficient adsorbent for controlling the formation of disinfection by-products (DBPs) in chlorinated drinking water. The Science of the total environment 2020. link 14 Ding S, Wang F, Chu W, Cao Z, Pan Y, Gao N. Rapid degradation of brominated and iodinated haloacetamides with sulfite in drinking water: Degradation kinetics and mechanisms. Water research 2018. link 15 Lee J, Sim W, Im Y, Hwang E, Heo J. Optimization of disinfection by-product analysis methods for IMO G9 approval. Marine pollution bulletin 2018. link 16 Beauchamp N, Laflamme O, Simard S, Dorea C, Pelletier G, Bouchard C et al.. Relationships between DBP concentrations and differential UV absorbance in full-scale conditions. Water research 2018. link 17 Kong FX, Wang XM, Yang HW, Chen JF, Guo CM, Zhang T et al.. The role of solubility on the rejection of trace organics by nanofiltration membrane: exemplified with disinfection by-products. Environmental science and pollution research international 2017. link 18 Li Z, Chen T, Cui F, Xie Y, Xu W. Impact of chitosan and polyacrylamide on formation of carbonaceous and nitrogenous disinfection by-products. Chemosphere 2017. link 19 Cheema WA, Kaarsholm KMS, Andersen HR. Combined UV treatment and ozonation for the removal of by-product precursors in swimming pool water. Water research 2017. link 20 Spiliotopoulou A, Hansen KM, Andersen HR. Secondary formation of disinfection by-products by UV treatment of swimming pool water. The Science of the total environment 2015. link 21 Kristiana I, Lethorn A, Joll C, Heitz A. To add or not to add: the use of quenching agents for the analysis of disinfection by-products in water samples. Water research 2014. link 22 Montesinos I, Gallego M. Speciation of common volatile halogenated disinfection by-products in tap water under different oxidising agents. Journal of chromatography. A 2013. link 23 Chu W, Gao N, Yin D, Deng Y, Templeton MR. Ozone-biological activated carbon integrated treatment for removal of precursors of halogenated nitrogenous disinfection by-products. Chemosphere 2012. link 24 Bond T, Goslan EH, Jefferson B, Roddick F, Fan L, Parsons SA. Chemical and biological oxidation of NOM surrogates and effect on HAA formation. Water research 2009. link 25 Krief S, Jamart A, Mahé S, Leendertz FH, Mätz-Rensing K, Crespeau F et al.. Clinical and pathologic manifestation of oesophagostomosis in African great apes: does self-medication in wild apes influence disease progression?. Journal of medical primatology 2008. link 26 Nnadi FN, Hernandez M, Fulkerson M. Evaluation of techniques for control of disinfection by-products: a pilot study. Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering 2004. link 27 Korshin GV, Wu WW, Benjamin MM, Hemingway O. Correlations between differential absorbance and the formation of individual DBPs. Water research 2002. link00042-8) 28 Rossman LA, Brown RA, Singer PC, Nuckols JR. DBP formation kinetics in a simulated distribution system. Water research 2001. link00059-8) 29 Chang CY, Hsieh YH, Shih IC, Hsu SS, Wang KH. The formation and control of disinfection by-products using chlorine dioxide. Chemosphere 2000. link00010-2) 30 Polderman AM, Krepel HP, Verweij JJ, Baeta S, Rotmans JP. Serological diagnosis of Oesophagostomum infections. Transactions of the Royal Society of Tropical Medicine and Hygiene 1993. link90026-m)